Skip to main content
Clinical Trials/IRCT20080921001264N12
IRCT20080921001264N12RecruitingPhase 3

Evaluating the effect of administration of Lactocare® probiotic on gasterointestinal symptoms and Anti-Ttg antibody in patients with celiac disease: Randomized controlled Clinical trial

Gorgan University of Medical Sciences0 sites98 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Recruiting
Sponsor
Enrollment
98

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to no limit (—)
Sex
All

Inclusion Criteria

  • Confirmation of celiac disease with small intestine biopsy
  • Measurement of antibody titer against tissue transglutaminase (Anti TTg)
  • Age above 18 years

Exclusion Criteria

  • Any recent infections
  • Concomitant inflammatory bowel disease (IBD)
  • Immune deficiency (acquired or non-acquired)
  • Taking drugs that affect the immune system (immune suppressors and stimulants)
  • Recent GI surgery
  • Taking NSAID painkillers or antibiotics in the last 6 weeks
  • Having cancer or being HIV positive
  • Cardiovascular diseases, glands, kidney, liver, neurological or mental malignancy
  • Pregnancy and breastfeeding
  • Alcohol and drug addiction
  • Participation in another similar study within the last 6 months
  • unwillingness to take probiotics
  • patient being out of reach

Investigators

Sponsor
Gorgan University of Medical Sciences

Similar Trials